Suggested remit: To appraise the clinical and cost effectiveness of Linvoseltamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6609
Provisional Schedule
- Committee meeting: 1:
- 01 December 2026
- Expected publication:
- 17 February 2027
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Regeneron Pharmaceuticals, Inc. (Linvoseltamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer Black Care
- Cancer52
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Myeloma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Cancer Physicians
- Blood and Marrow Transplantation Clinical Reference Group NHS England
- British Geriatrics Society
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Blood and Marrow Transplantation and Cellular Therapy
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Myeloma Society
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- • ADVANZ Pharma (dexamethasone)
- Amarox (lenalidomide, pomalidomide)
- Aspire Pharma (bortezomib, dexamethasone)
- Aurobindo Pharma – Milpharm (bortezomib)
- Biocon Pharma (lenalidomide)
- Biotech Pharma (bortezomib)
- Bristol Myers Squibb (mezigdomide)
- Chemidex Pharma (dexamethasone)
- Dr. Reddy's Laboratories UK (bortezomib)
- Gilead Sciences (anitocabtagene autoleucel)
- Glenmark Pharmaceuticals Europe (dexamethasone)
- Grindeks Kalceks UK (lenalidomide, pomalidomide)
- Janssen-Cilag, a Johnson & Johnson Company (bortezomib, daratumumab, talquetamab, teclistamab, ciltacabtagene autoleucel)
- Krka UK (dexamethasone)
- Menarini Stemline UK (selinexor)
- MSN Laboratories Europe (bortezomib)
- Pfizer (elranatamab)
- Pharmaand (panobinostat)
- Sandoz (bortezomib)
- Sanofi (isatuximab)
- Sun Pharma UK (bortezomib, lenalidomide)
- Synchrony Pharma (dexamethasone)
- Takeda UK (ixazomib)
- Teva UK (lenalidomide)
- Thornton & Ross (bortezomib, lenalidomide, pomalidomide)
- Viatris, formerly Mylan or Upjohn (lenalidomide, pomalidomide)
- Wockhardt UK (pomalidomide)
- Zentiva (dexamethasone, pomalidomide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematology
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 May 2026 | Invitation to participate |
| 17 March 2026 - 16 April 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 March 2026 | In progress. Scoping commenced. |
| 16 May 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual